Author

T. Kehrer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Biochemistry· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 4 Organism:human· 4 Research Focus:drug response / drug discovery· 3 Organism:mouse· 3 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1

Frequent Co-Authors

A. Garcia-Sastre· 6 shared R. Rathnasinghe· 5 shared L. Miorin· 4 shared S. Jangra· 4 shared A. Cupic· 3 shared E. Moreno· 3 shared H. van Bakel· 3 shared M. Schotsaert· 3 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersMicrobiology

A. Garcia-Sastre

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Impact of SARS-CoV-2 ORF6 and its variant polymorphisms on host responses and viral pathogenesis.

T. Kehrer, A. Cupic, C. Ye, S. Yildiz, M. Bouhhadou, N. A. Crossland, E. Barrall, P. Cohen, A. Tseng, T. Cagatay, R. Rathnasinghe, D. Flores, S. Jangra, F. Alam, N. Mena, , L. Miorin

This study shows SARS-CoV-2 ORF6 disrupts nucleo-cytoplasmic trafficking, inhibits IFN signaling, and modulates viral protein expression, with variant polymorphisms affecting its function.

bioRxiv · Oct 18, 2022Microbiology

The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters

L. Miorin, C. E. Mire, S. Ranjbar, A. J. Hume, J. Huang, N. A. Crossland, K. M. White, M. Laporte, T. Kehrer, V. Haridas, E. Moreno, A. Nambu, S. Jangra, A. Cupic, M. Dejosez, , A. E. Goldfeld

The paper shows that nitazoxanide inhibits SARS-CoV-2 replication and pathogenesis in human and hamster models, and synergizes with remdesivir against multiple variants.

bioRxiv · Feb 8, 2022 · PreprintImmunology

Discovery of a SARS-CoV-2 Broadly-Acting Neutralizing Antibody with Activity against Omicron and Omicron + R346K Variants

J. A. Duty, T. A. Kraus, H. Zhou, Y. Zhang, N. Shaabani, S. Yildiz, N. Du, A. Singh, L. Miorin, D. Li, K. Stegman, S. I. Ophir, X. Cao, K. Atanasoff, R. Lim, , R. Allen

This paper identifies a broadly neutralizing antibody, STI-9167, effective against SARS-CoV-2 variants including Omicron and Omicron + R346K, and describes its development for clinical trials.

bioRxiv · Jan 19, 2022 · PreprintMicrobiology

Unambiguous detection of SARS-CoV-2 subgenomic mRNAs with single cell RNA sequencing

P. Cohen, E. J. DeGrace, O. Danziger, R. Patel, E. A. Barrall, T. Bobrowski, T. Kehrer, A. Cupic, L. Miorin, A. Garcia-Sastre, B. R. Rosenberg

This study evaluates scRNA-Seq methods for detecting SARS-CoV-2 subgenomic mRNAs, finding that 10X 5' with extended R1 sequencing best captures these viral RNAs at single-cell resolution.

bioRxiv · Nov 22, 2021Microbiology

SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage

A. Escalera, A. S. Gonzalez-Reiche, S. Aslam, I. Mena, R. L. Pearl, M. Laporte, A. Fossati, R. Rathnasinghe, H. Alshammary, A. van de Guchte, M. Bouhaddou, T. Kehrer, L. Zuliani-Alvarez, D. A. Meekins, V. Balaraman, , T. Aydillo

This study shows SARS-CoV-2 variants of concern have mutations that increase spike cleavage and fusogenic capacity, enhancing viral transmission and cell entry.

bioRxiv · Aug 5, 2021 · PreprintMicrobiology

Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine.

R. Rathnasinghe, M. Salvatore, H. Zheng, S. Jangra, T. Kehrer, I. Mena, M. Schotsaert, T. Muster, P. Palese, A. Garcia-Sastre

This study shows that a live attenuated influenza virus vaccine lacking NS1 provides broad protection against respiratory viruses including SARS-CoV-2 by inducing both innate and adaptive immune responses.

bioRxiv · Apr 28, 2021Microbiology

Hepatitis C Virus Drugs Simeprevir and Grazoprevir Synergize with Remdesivir to Suppress SARS-CoV-2 Replication in Cell Culture

K. Bafna, K. White, B. Harish, R. Rosales, T. A. Ramelot, T. B. Acton, E. Moreno, T. Kehrer, C. A. Royer, A. Garcia-Sastre, R. M. Krug, G. T. Montelione

This paper evaluates HCV protease inhibitors as potential SARS-CoV-2 antivirals, finding that simeprevir and grazoprevir synergize with remdesivir to enhance antiviral activity against SARS-CoV-2 in cell culture.

bioRxiv · Dec 13, 2020Biochemistry